AB 1887 sets rare disease drug authorization timing

What happened

For contracts or policies issued, amended, or renewed from January 1, 2027, the rule applies when the drug is the only FDA-approved treatment for a rare disease, is prescribed by a specialist with relevant expertise, and is determined medically necessary by that specialist. The act defines rare disease as affecting fewer than 200,000 people in the United States. An initial request occurs when the provider or staff sends authorization to the carrier or its delegate, making that transmission evidence material to the clock.

Authorization must be completed within thirty days. Immediate approval is required if no approval or denial decision exists at the end of the period, or if a dispute with the provider or member remains ongoing then. The act preserves the separately referenced authorization timelines, including faster applicable processes, rather than granting thirty days for every case. Medi-Cal managed care is excluded from the plan provision. Request tracking must therefore retain both the qualifying clinical conditions and the actual initial transmission, without treating any expensive specialty drug as automatically within this pathway.

Why it matters

Specialty pathways need timely expert documentation and request tracking.

Implementation playbook

1. Confirm affected members, benefits and contracts against the final statutory scope. Managed Care · Due 2026-10-18
2. Confirm covered drugs, prescriber expertise and required request content; monitor response timing and escalate delays. Compliance · Due 2027-01-01
3. Validate updated workflows, communicate changes and monitor implementing guidance. Compliance · Due 2027-01-01

Sources

• AB1887 enacted final textOfficial · California Legislature · 2026-09-27 · Source review 2026-10-11